Harbour Biomed (guangzhou) Co. Ltd.

This study looked at the long-term safety of a drug called HBM9161 for people with generalized myasthenia gravis, a condition that causes muscle weakness. It involved 111 patients who had already completed a previous phase 3 study. The goal was to see if the drug is safe to use o…

This study tested a new medicine called HBM9161, given as a weekly shot under the skin, for adults with primary immune thrombocytopenia (ITP) — a condition where the immune system destroys platelets, raising the risk of bleeding. The trial included 36 people who had not responded…

This study tested an eye drop called HBM9036 in 577 Chinese adults with moderate to severe dry eye. The goal was to see if it reduces eye surface damage and improves symptoms better than a placebo. Participants used the drops for about two months, and doctors measured changes in …

This early-stage study tested a single injection of HBM9378 in 50 healthy Chinese adults to see if it is safe and how the body processes it. The goal was not to treat asthma but to gather safety and drug-level data. Participants were healthy, not asthma patients, so no direct ben…